Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amgen, which discovers, develops, manufactures and delivers innovative human therapeutics, has reached an agreement to settle its outstanding antitrust litigation with Ortho Biotech Products.
Subscribe to our email newsletter
Under terms of the agreement, Amgen will pay Ortho Biotech $200 million and the pending litigation in New Jersey District Court will be dismissed with prejudice. Amgen continues to deny that its challenged conduct was unlawful, and admits to no wrongdoing as part of the settlement agreement.
Ortho Biotech, a subsidiary of Johnson & Johnson, had alleged that discounts offered to oncology clinics on Amgen’s Neupogen and Neulasta and Aranesp products violated antitrust laws.
Kevin Sharer, chairman and CEO of Amgen, said: “We are pleased to have reached a settlement that puts this litigation behind us. We believe eliminating the expense and uncertainty of this suit is in the best interest of shareholders.”